Ethnic differences in achievement of cholesterol treatment goals. Results from the National Cholesterol Education Program Evaluation Project Utilizing Novel E-Technology II.

State University of New York Downstate Medical Center, Brooklyn, NY, USA.
Journal of General Internal Medicine (Impact Factor: 3.42). 05/2006; 21(4):320-6. DOI: 10.1111/j.1525-1497.2006.00349.x
Source: PubMed

ABSTRACT African Americans (AA) have the highest coronary heart disease mortality rate of any ethnic group in the United States. Data from the National Cholesterol Education Program Evaluation ProjecT Utilizing Novel E-Technology (NEPTUNE) II survey were used to assess ethnic differences in low-density lipoprotein cholesterol (LDL-C) goal achievement.
NEPTUNE II surveyed patients with treated dyslipidemia to assess achievement of treatment goals established by the Adult Treatment Panel III of the National Cholesterol Education Program. United States physicians working in primary care or relevant subspecialties enrolled 10 to 20 consecutive patients (May to September 2003), and patient data were recorded in Personal Digital Assistants and uploaded to a central database via the internet.
Among 4,885 patients receiving treatment for dyslipidemia, 79.7% were non-Hispanic white (NHW) and 8.4% were AA. Non-Hispanic white and AA patients had significantly different frequencies of treatment success, with 69.0% and 53.7%, respectively, having achieved their LDL-C goal (P<.001). African-American patients were more likely to be in the highest risk category, and less likely to be using lipid drug therapy, taking high-efficacy statins, and receiving care from a subspecialist, but the difference in goal achievement remained significant (P<.001) after adjustment for these and other predictors of treatment success.
The frequency of treatment success in dyslipidemia management was significantly lower in AA than NHW patients. Additional research is needed to elucidate reasons for this disparity and to evaluate strategies for improving goal achievement among AA patients receiving therapy for dyslipidemia.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Abstract Objective: British clinical guidelines recommend statins as first-line lipid-modifying treatment (LMT) for patients at high risk of cardiovascular disease (CVD). We undertook an observational study to assess total cholesterol (TC) and low-density lipoprotein cholesterol (LDL-C) levels in high-risk patients who were treated with atorvastatin monotherapy by UK general practitioners. Methods: This retrospective database study included patients with a prescription for atorvastatin monotherapy between November 30, 2008, and November 30, 2011, with the index date defined as the first atorvastatin prescription during this period. Eligible high-risk patients with evidence of coronary heart disease (CHD), atherosclerotic vascular disease (AVD), diabetes mellitus (DM), or familial hypercholesterolemia (FH) were required to have ≥1 TC and LDL-C measurement between 3 and 12 months after the index date, and continuous enrollment 1 year before and 1 year after the index date. Cholesterol levels were assessed using the National Institute for Health and Care Excellence (NICE) guidelines: TC <4.0 mmol/L or LDL-C <2.0 mmol/L. Results: Of 2,999 high-risk patients (60.2% men; mean [SD] age = 67.9 [10.6] years) meeting selection criteria, 23.9% 28.2%, 36.2%, and 11.6% received prescriptions for atorvastatin 10, 20, 40, and 80 mg, respectively (percents do not sum to 100 because of rounding). Across all doses, the mean (SD) follow-up TC was 4.08 (0.80) mmol/L and LDL-C, 2.08 (0.65) mmol/L. A large proportion of patients (88.8%) had TC <5.0 mmol/L. However, only 45.8% had TC < 4.0 mmol/L, and 46.5% had LDL-C <2.0 mmol/L. Although a larger proportion of patients with CHD/AVD + DM reached guideline-recommended lipid levels, only 63.7% of such patients had TC <4.0 or LDL-C <2.0 mmol/L, which are the current targets for this subgroup as recommended by NICE. Conclusions: Less than half of UK high-CVD-risk patients receiving atorvastatin monotherapy achieved guideline-recommended treatment targets for TC, and less than two-thirds of patients with CHD/AVD + DM had values below TC (4.0 mmol/L) or LDL-C (2.0 mmol/L). More effective lipid-lowering strategies may be warranted to optimize cholesterol lowering and target attainment in high-risk patients. Limitations of this study include its retrospective, observational nature.
    Current Medical Research and Opinion 02/2014; DOI:10.1185/03007995.2014.890926 · 2.37 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Life expectancy and cardiovascular health have improved dramatically for Americans over the past century, with marked declines in stroke and coronary heart disease morbidity and mortality. Distribution of these benefits, however, has not occurred equitably. Racial and ethnic minorities often receive inferior healthcare, even when their income and insurance status are similar to Caucasian patients. A large portion of these disparities are related to cardiovascular disease. Efforts in research and education and improvements in cultural competence are all ultimately underway. Specific tools and programs, including novel use of electronic medical records, are emerging, and in the future, they will hopefully assist in overcoming the differences in health and disease that many Americans experience. These differences may be approached by managed care and federal and academic center initiatives. This review describes what is being done presently and what needs to be considered in the future to combat these disparities.
    Current Cardiovascular Risk Reports 05/2007; 1(2):124-132. DOI:10.1007/s12170-007-0020-x
  • [Show abstract] [Hide abstract]
    ABSTRACT: Hyperlipidemia is a powerful and extremely common risk factor for cardiovascular disease (CVD) among all racial/ethnic groups. However, there are certain racial/ethnic differences in the prevalence of hyperlipidemia and in lipid profiles. In addition, the excess burden and clustering of other risk factors for CVD in racial/ethnic minorities will affect intensity of therapy and target goals for management of hyperlipidemia. Finally, genetic profiling with single nucleotide polymorphisms will help identify individuals with unique risk profiles and their ability to respond to pharmacotherapeutic agents. Both therapeutic lifestyle changes and statins are powerful agents for improving lipids, and for primary and secondary prevention of CVD. This paper describes findings of lipid profiles in various racial/ethnic minority groups, discuss the use and efficacy of statins in these populations, and clarify the impact of observed racial/ethnic differences in CVD risk and mortality.
    Clinical Lipidology 12/2009; 4(6):741-754. DOI:10.2217/clp.09.70 · 0.86 Impact Factor

Full-text (2 Sources)

Available from
May 16, 2014